SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : BSD Medical (Long Term Investment Oriented)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: pleonastic who wrote (117)2/21/2013 12:40:27 PM
From: pleonastic   of 178
 
Interpreting the subject post requires knowing when the "meta analysis" was done. Here is what I found:

By searching for “hyperthermia radiotherapy meta analysis 1861” (the "1861" is the total number of patients involved) I got a large number of hits. And, these actually referenced back to this work:



“Clin Oncol (R Coll Radiol). 2007 Aug;19(6):418-26. Epub 2007 May 10.



Hyperthermia: a potent enhancer of radiotherapy.



Horsman MR, Overgaard J.



Department of Experimental Clinical Oncology, Aarhus University Hospital, Aarhus, Denmark. mike@oncology.dk



Abstract



Hyperthermia is generally regarded as an experimental treatment with no realistic future in clinical cancer therapy. This is totally wrong. Although the role of hyperthermia alone as a cancer treatment may be limited, there is extensive pre-clinical data showing that in combination with radiation it is one of the most effective radiation sensitisers known. Moreover, there are a number of large randomised clinical trials in a variety of tumour types that clearly show the potential of hyperthermia to significantly improve both local tumour control and survival after radiation therapy, without a significant increase in side-effects. Here we review the pre-clinical rationale for combining hyperthermia with radiation, and summarise the clinical data showing its efficacy.”



Note the year: *2007* !! And, much of the data Horsman and Overgaard analyzed must have come from published work done substantially earlier. Large advances have been made since 2007 for hyperthermia combined with radiotherapy – AND similarly for chemotherapy and surgery! – AND for revolutionary advances in ablation!. This is just one example of the (unacceptable!) difficulties of getting new therapies into practice. The ponderous process of proving new therapies is simply shocking. I’m not suggesting that new therapies should not be carefully examined and proven before widespread use, just that the process should be far better funded and PUSHED (and early adopters should be protected against any poorly-based lawsuits). It is disgusting that hyperthermia and microwave ablation are still “struggling” despite being ***PROVEN PROVEN PROVEN ETC.*** as breakthrough therapies. It is now up to the more “venturous” (less hidebound is more accurate, IMO) doctors to take notice of and begin routinely using BSD M’s highly proven equipment.



I think my continual griping about our dysfunctional FDA is well justified, but a more fundamental problem is the lack of public funds to speed up the necessary trials.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News